Literature DB >> 9338497

Activity of a new glycopeptide antibiotic (LY333328) against enterococci and other resistant gram-positive organisms.

A P Fraise1, J Andrews, R Wise.   

Abstract

A new semi-synthetic glycopeptide, LY333328, was tested for in-vitro activity against 197 strains of enterococci including strains resistant to other glycopeptides. Activity was also assessed against species with intrinsic resistance to glycopeptides. For strains of enterococci tested the LY333328 MIC90s were < or = 0.5 mg/L. Enterococcus faecalis was less susceptible to LY333328 than other enterococci with a maximum MIC of 2.0 mg/L. Glycopeptide-resistant strains of enterococci were not more resistant to LY333328 than glycopeptide-susceptible strains but intrinsically resistant species had MICs between 4 and 8 mg/L.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9338497     DOI: 10.1093/jac/40.3.423

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  6 in total

1.  Vancomycin-Resistant Enterococcus: Infectious Endocarditis Treatment.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-06       Impact factor: 3.725

2.  Activity and diffusion of LY333328 in experimental endocarditis due to vancomycin-resistant Enterococcus faecalis.

Authors:  A Saleh-Mghir; A Lefort; Y Petegnief; S Dautrey; J M Vallois; D Le Guludec; C Carbon; B Fantin
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

3.  In vitro activities of LY333328 and comparative agents against nosocomial gram-positive pathogens collected in a 1997 global surveillance study.

Authors:  M L Zeckel; D A Preston; B S Allen
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

4.  Antimicrobial susceptibility patterns of enterococci causing infections in Europe. The European VRE Study Group.

Authors:  M A Schouten; A Voss; J A Hoogkamp-Korstanje
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

5.  Comparison of inhibitory and bactericidal activities and postantibiotic effects of LY333328 and ampicillin used singly and in combination against vancomycin-resistant Enterococcus faecium.

Authors:  A L Baltch; R P Smith; W J Ritz; L H Bopp
Journal:  Antimicrob Agents Chemother       Date:  1998-10       Impact factor: 5.191

6.  Oritavancin diphosphate.

Authors:  Dennis J Cada; Danial E Baker
Journal:  Hosp Pharm       Date:  2014-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.